Advertisement

Usefulness of Plasma Tissue Inhibitors of Metalloproteinases as Markers of Prognosis After Acute Myocardial Infarction

      Alterations in the balance of matrix metalloproteinase to tissue inhibitor of metalloproteinase (TIMP) are seen after acute myocardial infarction (AMI) and are associated with adverse left ventricular remodeling and prognosis in this setting. We aimed to investigate the association between TIMP levels and the occurrence of major adverse cardiac events (MACEs) after AMI. We measured plasma TIMP-1, -2, and -4 levels in 1,313 patients presenting with AMI. Subjects were followed over a median period of 520 days for the occurrence of MACEs. Clinical risk was assessed using the Global Registry of Acute Coronary Events (GRACE) score. All TIMP levels correlated with patient age and inversely with estimated glomerular filtration rate (all p values <0.001). Levels were higher in women versus men (p <0.001) and in subjects with a history of diabetes (TIMP-1, p <0.001; TIMP-2, p = 0.002; TIMP-4, p <0.001) or hypertension (TIMP-1, p = 0.031; TIMP-2, p <0.001; TIMP-4, p <0.001). TIMP-1 and TIMP-4 were higher in subjects with previous MI or angina (p <0.001). TIMP levels increased incrementally with quartiles of GRACE score (p <0.001). All TIMPs showed univariate association with the occurrence of MACEs (p <0.001). Areas under the receiver operator characteristic curve for prediction of MACE at 1 year were 0.61 for TIMP-1, 0.57 for TIMP-2, and 0.64 for TIMP-4. Combination of TIMPs with GRACE risk score revealed a greater area under the curve than GRACE score alone (0.72 vs 0.69, p = 0.0015). On multivariable Cox proportional hazards analysis, GRACE score (p <0.001) and plasma TIMPs (log TIMP-1, p = 0.017; log TIMP-2, p <0.001; log TIMP-4, p = 0.011) independently predicted MACEs. Using Kaplan-Meier analysis, the risk of MACEs increased incrementally with the number of TIMPs above their respective median (p <0.001 for all comparisons, log-rank test). In conclusion, higher plasma TIMP-1, -2, and -4 after AMI are associated with MACEs and provide additional prognostic information to that obtained from GRACE clinical risk scores alone.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Eagle K.A.
        • Lim M.J.
        • Dabbous O.H.
        • Pieper K.S.
        • Goldberg R.J.
        • Van de Werf F.
        • Goodman S.G.
        • Granger C.B.
        • Steg P.G.
        • Gore J.M.
        • Budaj A.
        • Avezum A.
        • Flather M.D.
        • Fox K.A.
        A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.
        JAMA. 2004; 291: 2727-2733
        • Fox K.A.
        • Dabbous O.H.
        • Goldberg R.J.
        • Pieper K.S.
        • Eagle K.A.
        • Van de Werf F.
        • Avezum A.
        • Goodman S.G.
        • Flather M.D.
        • Anderson Jr, F.A.
        • Granger C.B.
        Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE).
        BMJ. 2006; 333: 1091
        • Arakawa N.
        • Nakamura M.
        • Aoki H.
        • Hiramori K.
        Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction.
        J Am Coll Cardiol. 1996; 27: 1656-1661
        • Omland T.
        • Persson A.
        • Ng L.
        • O'Brien R.
        • Karlsson T.
        • Herlitz J.
        • Hartford M.
        • Caidahl K.
        N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes.
        Circulation. 2002; 106: 2913-2918
        • O'Brien R.J.
        • Squire I.B.
        • Demme B.
        • Davies J.E.
        • Ng L.L.
        Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF.
        Eur J Heart Fail. 2003; 5: 499-506
        • Richards A.M.
        • Nicholls M.G.
        • Yandle T.G.
        • Frampton C.
        • Espiner E.A.
        • Turner J.G.
        • Buttimore R.C.
        • Lainchbury J.G.
        • Elliott J.M.
        • Ikram H.
        • Crozier I.G.
        • Smyth D.W.
        Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction.
        Circulation. 1998; 97: 1921-1929
        • Gomez D.E.
        • Alonso D.F.
        • Yoshiji H.
        • Thorgeirsson U.P.
        Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.
        Eur J Cell Biol. 1997; 74: 111-122
        • Lubos E.
        • Schnabel R.
        • Rupprecht H.J.
        • Bickel C.
        • Messow C.M.
        • Prigge S.
        • Cambien F.
        • Tiret L.
        • Munzel T.
        • Blankenberg S.
        Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study.
        Eur Heart J. 2006; 27: 150-156
        • DeLong E.R.
        • DeLong D.M.
        • Clarke-Pearson D.L.
        Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.
        Biometrics. 1988; 44: 837-845
        • Kelly D.
        • Cockerill G.
        • Ng L.L.
        • Thompson M.
        • Khan S.
        • Samani N.J.
        • Squire I.B.
        Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study.
        Eur Heart J. 2007; 28: 711-718
        • Kelly D.
        • Khan S.
        • Cockerill G.
        • Ng L.L.
        • Thompson M.
        • Samani N.J.
        • Squire I.B.
        Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction.
        Eur J Heart Fail. 2008; 10: 133-139
        • Kelly D.
        • Khan S.Q.
        • Thompson M.
        • Cockerill G.
        • Ng L.L.
        • Samani N.
        • Squire I.B.
        Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction.
        Eur Heart J. 2008; 29: 2116-2124
        • Brown D.L.
        • Hibbs M.S.
        • Kearney M.
        • Loushin C.
        • Isner J.M.
        Identification of 92-kD gelatinase in human coronary atherosclerotic lesions.
        Circulation. 1995; 91: 2125-2131
        • Webb C.S.
        • Bonnema D.D.
        • Ahmed S.H.
        • Leonardi A.H.
        • McClure C.D.
        • Clark L.L.
        • Stroud R.E.
        • Corn W.C.
        • Finklea L.
        • Zile M.R.
        • Spinale F.G.
        Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
        Circulation. 2006; 114: 1020-1027
        • Yu W.H.
        • Yu S.
        • Meng Q.
        • Brew K.
        • Woessner Jr, J.F.
        TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix.
        J Biol Chem. 2000; 275: 31226-31232
        • Heymans S.
        • Schroen B.
        • Vermeersch P.
        • Milting H.
        • Gao F.
        • Kassner A.
        • Gillijns H.
        • Herijgers P.
        • Flameng W.
        • Carmeliet P.
        • Van de Werf F.
        • Pinto Y.M.
        • Janssens S.
        Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart.
        Circulation. 2005; 112: 1136-1144
        • Elmas E.
        • Lang S.
        • Dempfle C.E.
        • Kalsch T.
        • Hannak D.
        • Sueselbeck T.
        • Wolpert C.
        • Borggrefe M.
        • Brueckmann M.
        High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction.
        Clin Chem Lab Med. 2007; 45: 1360-1365
        • Strongin A.Y.
        • Collier I.
        • Bannikov G.
        • Marmer B.L.
        • Grant G.A.
        • Goldberg G.I.
        Mechanism of cell surface activation of 72-kDa type IV collagenase.
        J Biol Chem. 1995; 270: 5331-5338
        • Bertaux B.
        • Hornebeck W.
        • Eisen A.Z.
        • Dubertret L.
        Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases.
        J Invest Dermatol. 1991; 97: 679-685
        • Lambert E.
        • Dasse E.
        • Haye B.
        • Petitfrere E.
        TIMPs as multifacial proteins.
        Crit Rev Oncol/Hematol. 2004; 49: 187-198
        • Hudson M.P.
        • Armstrong P.W.
        • Ruzyllo W.
        • Brum J.
        • Cusmano L.
        • Krzeski P.
        • Lyon R.
        • Quinones M.
        • Theroux P.
        • Sydlowski D.
        • Kim H.E.
        • Garcia M.J.
        • Jaber W.A.
        • Weaver W.D.
        Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.
        J Am Coll Cardiol. 2006; 48: 15-20